Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease ...

Hemostasis Market Insight, Epidemiology and Market Forecast - 2032The hemostasis market is experiencing significant expansion, driven by inc ...

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape ...

In 2008, the largest automotive recall in history occurred when Takata Corp. air bags in several brands of cars were found to ...